Compare iShares MSCI Canada (TSX) (EWC) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs Neurocrine Biosciences Inc — how do they compare? iShares MSCI Canada (TSX) trades at $58.3 (market cap $7.14B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: Neurocrine Biosciences Inc is far larger — about 2× iShares MSCI Canada (TSX)'s market cap, and iShares MSCI Canada (TSX) is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Canada (TSX) for 57 Days and Neurocrine Biosciences Inc for 23 Days on average.
| EWC | NBIX | |
|---|---|---|
Market Cap | $7.14B | $14.60B |
Volume | 2,496,812 | 1,075,694 |
Sector | Broad Market / Factor | Health |
52-Week High | $62.64 | $185.50 |
52-Week Low | $49.72 | $123.10 |
Typical Hold Time | 57 Days | 23 Days |
Enterprise Value | — | $14.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWC is trading at $57.94, down 2.1% with a bearish technical signal as moving averages indicate selling pressure while oscillators remain neutral. The stock shows oversold conditions with RSI readings below 30, suggesting potential for near-term bounce. Recent news highlights Canada's trade tensions with the US and potential EU associate membership discussions creating market uncertainty.
The outlook remains cautious given trade policy risks and technical weakness, though oversold conditions may provide short-term opportunities. Key risks include US-Canada trade disputes and economic sensitivity to external shocks, while potential EU alignment could offer diversification benefits if negotiations progress favorably.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
